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Abstract
Background: Biopiracy – the use of a people’s long-established medical knowledge without acknowledgement or
compensation – has been a disturbing historical reality and exacerbates the global rich-poor divide. Bioprospecting,
however, describes the commercialization of indigenous medicines in a manner acceptable to the local populace.
Challenges facing bioprospectors seeking to develop traditional medicines in a quality-controlled manner include a
lack of skilled labor and high-tech infrastructure, adapting Northern R&D protocols to Southern settings, keeping
products affordable for the local population, and managing the threat of biopiracy. The Malagasy Institute of
Applied Research (IMRA) has employed bioprospecting to develop new health treatments for conditions such as
diabetes and burns. Because of its integration of Western science and Malagasy cultural traditions, IMRA may
provide a useful example for African and other organizations interested in bioprospecting.
Discussion: IMRA’s approach to drug development and commercialization was adapted from the outset to
Malagasy culture and Southern economic landscapes. It achieved a balance between employing Northern R&D
practices and following local cultural norms through four guiding principles. First, IMRA’s researchers understood
and respected local practices, and sought to use rather than resist them. Second, IMRA engaged the local
community early in the drug development process, and ensured that local people had a stake in its success. Third,
IMRA actively collaborated with local and international partners to increase its credibility and research capacity.
Fourth, IMRA obtained foreign research funds targeting the “diseases of civilization” to cross-fund the development
of drugs for conditions that affect the Malagasy population. These principles are illustrated in the development of
IMRA products like Madeglucyl, a treatment for diabetes management that was developed from a traditional
remedy.
Summary: By combining local and international research interests, IMRA has been able to keep its treatments
affordable for the Malagasy population. Our analysis of IMRA’s history, strategy, and challenges suggests that other
developing world institutions seeking to use bioprospecting to address issues of local access to medicines would
be well-advised to treat traditional medical knowledge with respect and humility, share its benefits with the local
community, and pursue strategic partnerships.
Background
Finding a new lead in drug discovery is a tremendous
challenge—much like seeking a needle in a haystack.
One resource for success in the search for bioactive
compounds is biodiversity. Bioprospecting is the com-
mercialization of indigenous medicines in a manner
acceptable to the local populace [1]. In addition to
promoting economic development of the host country,
bioprospecting is often associated with sustainability and
the preservation of local biodiversity. Bioprospecting
stands in contrast to biopiracy in which local and tradi-
tional stakeholders are neither consulted nor benefit
from the development of drugs based on local flora and
fauna.
In recent years, the efforts of several bioprospecting
organizations have led to promising drugs being devel-
oped to treat conditions from cancers to malaria [2].
During its 52 year history, the Malagasy Institute of
Applied Research (IMRA) has documented the
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over 40 plant-based drugs and ‘nutraceuticals’ for local
use and export [3]. IMRA’s early achievements are tied
to its founder Dr. Albert Rakoto-Ratsimamanga’s devel-
opment of the diabetes drug Madeglucyl; the discovery
and development of this drug provide a microcosm of
IMRA’s processes.
We used a case study design. Our analysis is based on
interviews with key informants including site visits in
Madagascar, and literature analysis. Where not specifi-
cally noted or referenced, the report is based on analysis
of these interviews. Semi-structured, face-to-face inter-
views took place in Antananarivo, Madagascar in
O c t o b e r2 0 0 7 .T h e s ew e r ef o l l o w e db ye m a i ld i s c u s -
sions, updates, and feedback with IMRA from August to
October 2009. Analysis of transcripts was supported by
qualitative data analysis software ATLASti and NVivo.
We also analyzed background documents from peer-
reviewed literature, news items, reports, and books, as
well as reports from the Government of Madagascar,
World Health Organization, World Intellectual Property
Organization, and the organizational website of IMRA.
IMRA was asked to fact-check the case study; the analy-
sis and interpretation is our own. All quotes are from
the interviews unless noted, and with permission. This
study was approved by the Office of Research Ethics of
the University of Toronto.
This article analyzes the history and studies the les-
s o n sl e a r n e db yI M R A ,a n di nd o i n gs os u g g e s t sh o w
research institutions in the developing world might
approach the challenge of making effective use of their
biodiversity resources. After discussing IMRA’s approach
to bioprospecting, we go on to examine the company’s
partnerships and operating strategy. We then consider
lessons from IMRA, and close by considering its rele-
vance to the broader question of ethnomedicine’s poten-
tial benefit for global health.
Discussion
Madagascar: biodiversity threatened by biopiracy
With over 5% of the world’s biodiversity on 0.004% of
the world’s landmass, Madagascar is one of the world’s
top three conservation hotspots [4-6]. The Malagasy
people, however, are the seventh poorest people in the
world. Madagascar’s political history, from French colo-
nial rule in the 19
th and 20
th centuries to a military
coup in 2001 and more recent political troubles, has
only exacerbated the historic divides within its ethnically
heterogeneous population [4,5].
The threat of biopiracy remains prevalent in Madagas-
car. The Malagasy people reportedly did not share the
benefits of the commercialization of the Madagascar
periwinkle (Catharanthus roseus) into the drug Vincris-
tine by a Northern pharmaceutical company [7].
From humble beginnings to modern research institute
In 1958, with a personal investment derived from royal-
ties accrued through his previous discoveries, Dr. Albert
Rakoto-Ratsimamanga founded IMRA [8]. Being of
noble birth, Rakoto-Ratsimamanga was one of the few
Malagasy of his generation who was educated abroad,
and received doctorates in both science and medicine at
the Université de Paris. On his return, Rakoto-Ratsima-
manga applied his training to aid his fellow citizens. As
a result of a life dedicated to the betterment of those
less privileged than himself, Rakoto-Ratsimamanga was
honored by his fellow citizens as “Malagasy Man of the
20th century.”
Since Rakoto-Ratsimamanga’s death in 2001, IMRA
has been headed by his wife, Suzanne Ratsimamanga.
Under her leadership, IMRA has grown into an organi-
zation that provides permanent employment for a staff
of about 150, and seasonal employment for almost
15,000 rural villagers.
While IMRA’s core purpose is to conduct research
and develop and market affordable drugs, the organiza-
tion also aims to promote Malagasy culture and pre-
serve local biodiversity. According to its management, at
the time of the case study IMRA was comprised of four
main divisions [9]:
￿ A department of research and development (R&D).
R&D is a non-profit division of IMRA. IMRA also
trains the next generation of Malagasy researchers
(mainly through collaborations with local and inter-
national universities).
￿ A biodiversity unit that includes a botanical garden
and lab for collecting and preserving endangered
medicinal plants.
￿ A department for the production, quality control,
distribution, and export of products (including
drugs, nutraceuticals, oils, and cosmetics). This divi-
sion is separately incorporated as Soamadina Lim-
ited, and is a for-profit entity.
￿ A health clinic which offers free health care con-
sultations to local villagers.
Madeglucyl: a novel diabetes drug
In 1965, Albert and Susan Rakoto-Ratsimamanga dis-
covered that traditional healers were using a novel
method to diagnose diabetes: healers asked patients to
urinate next to an anthill, and observed the reaction of
the ants. While ants avoid the urine of healthy humans,
the urine of diabetic patients is rich in glucose and is
especially attractive to the insects. After watching hea-
lers prescribe a plum-like fruit from the plant Syzygium
cumini to treat their patients, the Ratsimamangas
decided to systematically study this plant.
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IMRA had to limit the local practice of cutting down
Syzygium cumini trees for fuel and construction mate-
rial. IMRA addressed this through dialogue that con-
vinced the local villagers that Syzygium cumini trees
were more valuable for their fruit than their wood.
Designing an effective system of seed collection was
another challenge. The seeds, which contain the active
medicinal ingredient, have to be harvested and quickly
processed during the short peak period of fruit growth.
From the beginning, IMRA believed that the rural peo-
ple who populated the areas where the tree grew were
the ones best suited to aid the seed collection process.
After a short training period, the local people took
quickly to seed collection and drying. Improvements to
their supply chain network meant that by 1998, IMRA
was able to harvest 20 tons of seed during the short col-
lection season.
IMRA’s efforts resulted in the creation of a commer-
cially produced drug, Madeglucyl (a timeline for Made-
glucyl’s development can be found in Table 1). Pre-
clinical studies on rats established the efficacy and safety
of the drug, and led to clinical trials in Madagascar,
Germany, and the United States. In December 1997,
Madeglucyl was approved as a licensed medicine in
Madagascar; although a clinical trial has been conducted
in the US, it is reportedly only available as a herbal sup-
plement there [9].
Clinical studies conducted by IMRA have shown
Madeglucyl to be effective in helping to manage both
Type I and Type II diabetes; in Type I diabetes, it
reportedly reduces (but does not eliminate) daily insulin
requirements [9]. Although Madeglucyl is presently sold
mainly in Madagascar, it has recently been launched in
the international market under the trade name Glucanol
Forte
TM [10].
The drug discovery process at IMRA
IMRA uses a multi-disciplinary approach to drug dis-
covery that represents local adaptation of the pipeline
approach used by the pharmaceutical industry. The first
step involves conducting surveys with villagers and tra-
ditional health practitioners to gather information on
indigenous practices to treat a particular condition.
Through this, researchers are able to compile a biblio-
graphy of plants traditionally used to treat the disease in
question. IMRA also obtains the consent of tribal elders
and local heads before encroaching into their traditional
sphere of authority.
The next step involves the collection and botanical
study of promising plants. The chemists on the team
then proceed to extract active compounds that may be
responsible for the plant’s efficacy. Pharmacologists test
compounds of interest using in vitro and in vivo models
[11]. The safety and toxicity of the prospective com-
pound is then studied, followed by pre-clinical and clini-
cal studies. (The protocol IMRA uses for these studies is
the one developed in 2002 by the Traditional Medicine
Program which is part of the WHO regional office for
Africa [12].) Finally, the drug is brought to market,
which involves regulatory, financial, and marketing con-
siderations as discussed later.
Due to equipment shortages at IMRA, pre-clinical
trials are often done abroad in collaboration with part-
ners. The wait times caused by such an arrangement
often prolong the time it takes to bring a promising
drug to market, and are a limitation of working in a
low-resource setting.
Working with local culture
While IMRA’s approach appears simple, implementing it
has required a nuanced understanding of Malagasy cul-
ture. The revered stature of healers in Malagasy society
means that ordinary villagers may be unlikely to ques-
tion their methods, as an inquisitive attitude could be
interpreted as an affront to the healer’s authority. Yet
IMRA’s consultation process with traditional health
practitioners may reveal medicines that the healers
believe to be efficacious and benign, but which in reality
may be ineffective or even harmful. As Madam Baholy
Table 1 Timeline for IMRA and Madeglucyl development
1958 Albert Rakoto-Ratsimamanga establishes IMRA
1965 Albert Rakoto-Ratsimamanga and Suzanne Ratsimamanga begin to work with local healers
1970 IMRA launches its Syzygium cumini (Madeglucyl) project
1984 Initial license for Madeglucyl is registered in Paris
1985 Professors study and experiment with Syzygium cumini seeds at IMRA and the University of Paris.
1993 IMRA is awarded official status as a foundation by government decree
1996 Second license is issued, granting Madeglucyl international recognition
1997 New Drug Application for Madeglucyl is filed and approved in Madagascar
1998 Total harvest of Syzygium cumini seeds reaches 20 tonnes
2007 Production capacity for Madeglucyl reaches 20kg/day (5g/package)
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the population doesn’t tell the traditional healer that
they [still] have a headache...they don’t want to tell it to
the traditional healer because they are afraid...they don’t
want the traditional healer to [say] that ‘Ah, you don’t
have confidence in me? Don’t come to see me after.’”
Understanding the rationale behind IMRA’s approach
requires an anthropological perspective of illness. In
sociocentric societies such as Madagascar, visiting the
traditional healer when ill is itself part of the healing pro-
cess. While such a visit may facilitate a “hoped for result”
(i.e. a cure that has a biomedical basis), it always affects
an “expected result” (i.e. a confirmation of the illness
which in turn reinforces the worldview of the given
society) [13]. Accordingly, the healer’sm e t h o d s( e . g .
always prescribing a tea for any illness) may be eliciting a
cure through the placebo effect. While both the healer
and the healed may defend the efficacy of the tea, the
cure it elicits could be culturally specific and have no bio-
logical basis. Thus, bioprospecting requires an under-
standing of local culture if one is to avoid wasting time
and money. According to Mr. Denis, a lab manager at
IMRA: “It’s not true that the plants that are [traditionally]
used for diabetes [are always] efficacious for diabetes; so
we screen [more plants], or go for something else.”
Despite the challenges, researchers at IMRA are con-
vinced of the benefits of scientifically studying Madagas-
car’s biodiversity. Any phytomedicines developed
through such a process are likely to be readily accepted
by the Malagasy people who “are used to taking plants”
according to Madam Baholy Rafatro.
Regulatory affairs
In 2002, the Ministry of Health in Madagascar estab-
lished the Department of Traditional Medicine and
Pharmacopoeias to oversee the development of laws and
regulations related to Traditional Medicines and Com-
plementary and Alternative Medicines (TM/CAM) [14].
IMRA works closely with the Ministry and appears to
view the regulatory establishment as a friend rather than
a foe. Nevertheless, IMRA’sC S OD r .R a s o a n a i v os u g -
gests that the regulatory climate in Madagascar is not
yet mature: “The idea of protection of intellectual prop-
erty rights is very important or else biopiracy will
continue.”
While pharmaceutical drugs are regulated in Madagas-
car, most traditional medicines are classified as over-the-
counter drugs and are thus not regulated. There are,
however, regulations in place to ensure that manufac-
turers adhere to Good Manufacturing Practices (GMPs),
and produce herbal drugs according to the information
contained in the pharmacopoeias. Despite poor over-
sight, TM/CAMs command the trust of many Malagasy
people.
One regulatory challenge relevant to bioprospecting is
potential discontent between modern doctors / research-
ers and traditional healers. While the former consist of
physicians educated in the Western biomedical para-
digm, the latter maintain the trust of the Malagasy
population, and in recent times have been licensed,
which has allowed them to practice backed by the legiti-
macy of the state. The frustration experienced by physi-
cians was expressed by Madam Baholy Rafatro:
“Sometimes people go listen to them [the healers]
because traditionally they go listen to them, and they
ignore the tests and other advice that the doctor has
given them.”
Partnerships and collaborations: bioprospecting under
the CNRS program
According to our key informants, IMRA has actively
sought external funding to support bioprospecting activ-
ities, notably through European Union (EU) grants
aimed at promoting bioprospecting. Table 2 lists some
of IMRA’s main local and international R&D partners as
of 2009. Along with supporting bioprospecting, these
partnerships and collaborations aid in training the next
generation of Malagasy researchers.
IMRA’s CSO, Dr Rasoanaivo, described two biopros-
pecting programs that have been conducted in Madagas-
car. In July 2004, the Centre National de la Recherche
Scientifique (CRNS) in France signed a memorandum of
understanding with the University of Antananarivo, with
the participation of IMRA. Under this bioprospecting
project, more than 800 diverse plants were collected
since 2004; in August 2009, the project was renewed for
three years. Plants were reportedly collected with prior
consent of the Ministère de l’Environnement, des Eaux
et Forets et du Tourisme, and extracts exported for
screening after an agreement was signed with the Direc-
tion de la Préservation de la Biodiversité.
A second project called PHYTOCHIK, funded by the
Centre de Recherche et de Veille sur les Maladies émer-
g e n t e sd a n sl ’Océan Indien (CRVOI) aims to search the
area’s biodiversity for compounds targeting the Chikun-
gunya virus on the Indian Ocean islands. It involves
multilateral cooperation between Mauritius, Madagascar
(IMRA), Réunion Island, France, and Belgium.
Funding through a third project from the International
Cooperative Biodiversity Groups (ICBG) reportedly
involved agreements with local villagers, and has aided
the development of infrastructure in Madagascar,
including the the construction of a new laboratory at
the University of Antananarivo and equipment upgrades
at a laboratory at the University of Fianarantsoa [15,16].
According to key informants at IMRA, these labora-
tories will play a role in the extraction of active com-
pounds from medicinal plants in the future.
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IMRA has found raising the capital necessary to sustain
its operations to be challenging. This problem is made
worse by the lack of funding by the Madagascar govern-
ment for research activities.
As a result, IMRA relies on revenues obtained from
the sales of its products, as well as research funding
from international organizations to sustain its opera-
tions. According to Mr Nivo Rakotoson, IMRA’sc o m -
mercialization representative, up to 60% of IMRA’s
revenues are generated through exports (mainly to
European partners in France, Germany, and Italy),
while 40% are obtained from local sales. Exports are
essential to IMRA’s viability, as the company makes a
profit of up to 50% on exports, while only maintaining
a 10-15% margin on local products to enhance local
affordability.
While IMRA’s revenues are reportedly growing at a
rate of over 8% per annum, it remains reliant on its star
product Madeglucyl, which accounts for up to 30% of
its product revenues. (See Table 3 for a list of other pro-
ducts.) To support its long-term success, IMRA’sc o m -
mercial arm, Soamadina, channels 30% of its profits
back to IMRA, thereby allowing for capacity-building
and investments in research and development.
Marketing and distribution
IMRA’s marketing strategy is simple: If it works well, it
will sell. Because of its status as a research-based organi-
zation, most of IMRA’s efforts are focused on drug dis-
covery, and less attention is paid to the
commercialization of products. According to Mr Nivo
Rakotoson, IMRA’s commercialization representative,
the Ministry of Health authorizes IMRA to sell directly
to hospitals, and IMRA therefore promotes its products
through hospital tours where its representatives commu-
nicate with doctors.
IMRA owns a network of over 95 pharmacies
throughout Madagascar, which serves as a main distri-
bution channel for its products locally. In smaller vil-
lages that lack a pharmacy, IMRA’sp r o d u c t sa r es t i l l
usually available at the local “depots de medicaments”.
Table 3 lists IMRA’s main products. Despite efforts to
keep its products accessible to the Malagasy population,
IMRA’sp r o d u c t sa r es t i l le x p e n s i v ef o rm o s tv i l l a g e r s ,
and keeping prices low remains a challenge. Increasing
Table 2 IMRA’s main partnerships and collaborations
Partner name Country Nature of collaboration
Ministry of Health Madagascar Collaboration on regulatory affairs. The Ministry awards IMRA a contract to sell its
products to local hospitals.
Sanofi-Aventis (pharmaceutical company) France Provides equipment and materials for labs at IMRA, and funding. Laboratory and
pre-clinical tests (e.g. structure elucidation of biomolecules). Technology transfer
from Paris to Madagascar.
Institut de Chimie des Substances Naturelles, CNRS
(National Centre for Scientific Research)
France Work on a bioprospecting project to bring biological extracts and natural
products into drug development. Scientific training of IMRA researchers.
University of Belgium Belgium Laboratory and pre-clinical tests. Scientific training of researchers. Funding and
equipment.
Università degli Studi di Roma “La Sapienza” Italy Phytochemical work on Madagascar plants.
Bayer (pharmaceutical company) Germany Assistance to IMRA with exports. Technical expertise.
NAPRECA (National Product Research Network for
Eastern and Central Africa)
Regional NAPRECA is a regional consortium that aims to stimulate the development of
natural products research in Africa by coordinating such efforts.
RITAM (Research Initiative on Traditional Anti-
malarial Methods)
Global RITAM is an international consortium of researchers working on traditional
medicines for malaria.
WHO (World Health Organization) Global Work on a project to screen for medicinal plants to treat malaria.
Table 3 Key IMRA products [21]
Product name Plant species Purpose Development Stage
Madeglucyl / Glucanol
Forte™
Syzygium
cumini
Anti-diabetic In local and international
markets
Triterpenes
constituents
Centella asiatica Wound-healing agent (treats intense burns, leprous wounds and inflamed
ulcers) / Cosmetic ingredients
In market
Tazopsine derivative Strychnopsis
thouarsii
Prophylactic anti-malarial Early stage development
TMM Plant mixture Anti-leprosy In market
ODY VATO Hylocereus
genus
Against kidney stones In market
Dangitsyl Plant mixture To treat erectile dysfunction In market
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mation in its production facilities are two ideas that
IMRA representatives discussed which might aid in this
effort.
IMRA exports its products to European countries such
as France, Germany, and Italy [10]. As well, according to
Mr Rakotoson IMRA has “loyal clients” overseas who
purchase plant products such as essential oils over the
internet. From the intervi e w s ,i ta p p e a r st h a tI M R A ’s
ability to secure foreign buyers for its products is signifi-
cantly aided by its status as a one-stop authority on
Madagascar’s traditional biodiversity.
The future
In a sign of international recognition of IMRA, Dr. Phi-
lippe Rasoanaivo, IMRA’s CSO, was recently awarded
the Sven Brohult Award by the International Foundation
for Science (IFS) for his research into traditional plants
utilized by healers in Madagascar [17].
IMRA is developing relationships with European
companies to build a new production facility where
drugs are manufactured according to international
standards. IMRA also intends to expand the market
for Madeglucyl to other African nations in the next
few years, and has expressed interest in working with
other African national health authorities to create
commercial links.
Other phytomedicines are being developed by IMRA,
as shown in Table 3. Madecassol, a wound-healing
agent developed from Centella asiatica, is used to treat
burns, ulcers and leprous wounds. Researchers at IMRA
are also working on an anti-malarial compound, tazop-
sine. Derived from the bark of Strychnopsis thouarsii,
tazopsine has been used for years as an ingredient in a
herbal tea remedy for malaria. Tazopsine works by tar-
geting the early stages of malarial infection, decreasing
the chance of resistance developing [18]. Researchers at
IMRA are hopeful that laboratory tests on tazopsine var-
iants will produce one that is of low toxicity, and hence
suitable for human clinical trials.
While IMRA possesses an international outlook, it
continues to pay attention to developing treatments for
conditions that are widespread in the Malagasy popula-
tion, such as malaria, pulmonary problems, and diar-
rheal diseases. As Mr Guy Rakotoson, IMRA’s Head
Administrator puts it, “It’s really the philosophy of the
foundation to be at the service of the Malagasy
population.”
Lessons learned
IMRA was designed with Madagascar in mind. Where it
hit roadblocks and challenges, it found solutions
grounded in local realities and constraints. Here, we
outline lessons from IMRA’s experience that illustrate
how Southern innovators may utilize indigenous biodi-
versity to pursue pharmaceutical development.
Work with local culture
Much of IMRA’s success comes from respecting Mala-
gasy traditions and cultural norms, and using rather
than resisting them. Themselves Malagasy, IMRA’s
researchers understand local customs. An appreciation
of the host country’s culture is important if problems,
such as the tension between modern physicians and tra-
ditional health practitioners in Madagascar, are to be
anticipated and resolved. Bioprospectors must also be
careful to scientifically validate local practices if they
wish to avoid wasting resources investigating false leads.
On the health delivery side, in medically pluralistic
societies such as Madagascar where over 80% of the
population uses traditional medicines as a first source of
treatment, local populations may more readily accept
phytomedical cures that are cheap, non-invasive, often
already trusted, and easy to effect in a low-resource
setting.
While “work with local culture” is an easy phrase to
agree with, the process of local adaptation can be extre-
mely difficult to execute. Part of IMRA’ss u c c e s si nt h i s
regard seems to have come from Albert Rakoto-Ratsi-
mamanga’s combination of foreign training and experi-
ence with deep local knowledge, which may suggest the
value of leadership which is intimately familiar with
relevant cultures. Finding such motivated and cross-
trained leadership is one barrier to adopting an IMRA-
like approach elsewhere; others include cultivating an
attitude of humility toward traditional medicine while
being grounded in solid science, and the tendency for
traditionalists to reject biomedicine.
Engage and share benefits with local communities
Southern innovators may wish to engage the local com-
munity early in the drug development process. Many of
IMRA’s challenges, such as its initial difficulty in estab-
lishing a supply network of traditional plants and seeds
and its efforts to combat biopiracy, can be seen as dif-
ferent facets of the single problem of local adaptation. A
single strategy—bringing the local population into the
organization as part of its discovery, harvesting, and dis-
tribution systems—successfully addressed all of these
concerns and helped bridge the divide between ethno-
medicine and biomedicine in conservative Malagasy
society.
It is also advantageous for innovators to ensure that
locals have a stake in their company’s success, and vice
versa. IMRA was not gifted with the same markets as
North American or European pharmaceutical organiza-
tions; it had to make its products available to a poor
population suspicious of Western medicine. Through its
benefit-sharing practices that help local villagers to
profit from the organization’s success, IMRA claims to
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Malagasy populace, while at the same time building a
strong relationship with its local customer base.
Use partnerships for capacity-building and credibility
It is beneficial to collaborate with local and international
partners who have complementary strengths. IMRA was
challenged by delays in its research caused by the low-
resource base of Madagascar, and at the same time
faced a shortage of skilled personnel. Through its part-
nerships, IMRA increased its credibility and research
capacity, and benefited from a transfer of research dol-
lars from the global North to the global South.
Poor infrastructure and lack of access to resources
common in the West remain key challenges associated
with working in a developing country. Despite these
challenges, IMRA aims to keep itself relevant by invest-
ing in both its equipment and its people. One reason
why foreign universities and corporations have been
willing to cooperate with IMRA is because it has con-
formed to internationally accepted standards of science.
The IMRA case illustrates the need to invest in
human capital by training researchers through interna-
tional collaborations and studies. This “capacity-build-
ing” may prove costly in the short-term, but is vital in
the long-term to ensure that local scientists possess the
ability to conduct significant research. However, despite
such efforts the number of skilled scientific personnel in
Madagascar is limited, and IMRA has experienced diffi-
culty filling some of its positions.
Leverage both local strengths and global markets
Southern research institutions can leverage their low-
resource setting as a strength. Being situated in Mada-
gascar, IMRA is able to market itself as a local authority
on the island’sb i o d i v e r s i t y .I M R A ’s research capacity
and reputation makes it an appealing partner for North-
ern groups seeking to preserve and sustainably utilize
the world’s biodiversity. This strategy demonstrates the
potential of adapting research and business methods to
local settings, rather than necessarily trying to change
the local situation to fit an international market.
In IMRA’s case, the profits generated by exports help
keep its products affordable for the local populace, which
thus benefits from IMRA’s presence through both access
to medicines and increased economic opportunity. While
IMRA’s focus is local and it remains committed to
research that will lead to the development of affordable
drugs for Madagascar, the organization also looks for for-
eign research dollars. Researchers at IMRA have been
able to successfully combine local and international
research interests. Other institutions and organizations in
similar circumstances may consider coupling funds for
projects aimed at combating the “diseases of civilization”
with research into conditions prevalent in the South.
Summary
This article has analyzed the history, challenges, and les-
sons of IMRA, and in doing so suggested how research
institutions and countries in the developing world might
make effective use of their biodiversity resources.
Because of its integration of Western science and local
cultural traditions, IMRA may provide a useful example
for African and other organizations interested in bio-
prospecting. It may also be worth considering the value
of having a relatively well-resourced national organiza-
tion to facilitate development and production of com-
pounds from local biodiversity resources.
As countries from Cameroon to Costa Rica harness
their biodiversity and ethnomedical knowledge to propel
their economies into the 21
st century [2], the need for a
holistic approach to bioprospecting, one that carefully
considers the interest of all stakeholders, will only grow.
This is particularly relevant in the African context
where ethnomedical knowledge has traditionally been
passed down from generation to generation through the
oral tradition [19]. The lack of written records and the
presence of rare medicinal plants on privately owned
lands has limited foreign access to ethnobotanical infor-
mation, making cooperation with local actors all the
more necessary.
IMRA has aimed to adopt an approach to scientific
research that integrates health care, biodiversity conser-
vation, and production. In the course of its work, IMRA
has advocated practices that protect the environment,
respect local culture, and empower local populations to
share in the economic benefits of bioprospecting.
IMRA’s relationship to traditional Malagasy healing has
been important to the organization’sa c h i e v e m e n t st o
date.
Northern organizations seeking to bioprospect in the
global South should be aware of past biopiracy inci-
dents, and of the risk of creating new power differentials
and exacerbating existing ones in post-colonial African
s o c i e t y[ 2 0 ] .S t o k e db yi d e n t i t yp o l i t i c sa n dab r o a d e r
debate about the degree to which traditional knowledge
should be protected, a number of local actors have
called for increased protection. In reality, the middle
ground as represented by organizations like IMRA
between complete protectionism and unfettered access
to ethnomedical knowledge may represent the best hope
of pushing forward the boundaries of medical research
[21-23].
O n eg o a lo ft h i sa n a l y s i so fI M R Ah a sb e e nt oh e l p
inform those who wish to start, partner with, invest in,
or simply better understand organizations in the devel-
oping world that engage in bioprospecting to tackle glo-
bal health challenges. Given the potential of traditional
medicines to address issues of local access to healthcare,
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well as to identify good practices and potential policy
interventions to mobilize the developing world’sp h a r -
maceutical potential.
Organizations may wish to consider the principles dis-
cussed in this article: treating traditional medical knowl-
edge with respect and humility, sharing its benefits with
the local community, developing a collaborative research
and funding base, and translating research into appro-
priate health products with local impact. In doing so,
organizations may increase their chances of bridging the
divide between ethnomedicine and biomedicine in order
to develop new health treatments.
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